ABCL Revenue
Quarterly revenue, the top-line sales a company books before any costs are subtracted.
Revenue
Latest: $4M (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | $12M |
| 2023Q2 | $10M |
| 2023Q3 | $7M |
| 2023Q4 | $9M |
| 2024Q1 | $10M |
| 2024Q2 | $7M |
| 2024Q3 | $7M |
| 2024Q4 | $5M |
| 2025Q1 | $4M |
| 2025Q2 | $17M |
| 2025Q3 | $9M |
| 2025Q4 | $45M |
| 2026Q1 | $8M |
| 2026Q2 | $4M |
Other Indicators
Other ABCL Charts
More quarter-by-quarter fundamentals for AbCellera Biologics Inc.
1 / 6
EPS
Free Cash Flow
FCF Margin
Cumulative FCF
Shares Outstanding
Total Assets
Healthcare Comparison
1 / 3
Latest Revenue: $4M (2026Q2); -76.3% YoY; -28.8% CAGR (3.25y).
Across the 14 quarters from 2023Q1 to 2026Q2, Revenue ranged from $4M in 2026Q2 to $45M in 2025Q4.